» Articles » PMID: 27303077

Evaluation of the Impact of Corticosteroid Dose on the Incidence of Hyperglycemia in Hospitalized Patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Overview
Journal Hosp Pharm
Publisher Sage Publications
Date 2016 Jun 16
PMID 27303077
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Guidelines recommend systemic corticosteroids for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) albeit in lower doses than studies that cemented corticosteroids' place in therapy. Corticosteroids potentiate hyperglycemia, however it is undetermined how corticosteroid dose impacts hyperglycemia incidence.

Objectives: To establish whether a greater incidence of steroid-induced hyperglycemia (SIHGLY) exists for high- versus low-dose corticosteroids.

Methods: Patients with primary discharge diagnosis 491.21/491.22 in a community hospital were retrospectively reviewed and divided into tertiles based on corticosteroid dosage. Baseline characteristics and primary endpoint were statistically assessed between tertiles using logistic regression analysis. A Cox proportional hazards (CPH) model adjusted for potential covariates. Post hoc analysis for primary outcome and CPH model was run removing non-insulin dependent diabetics because of disproportionate event count. A secondary endpoint used a Kaplan-Meier curve to evaluate time to event between tertiles.

Results: Tertile divisions were 125 and 187.5 mg methylprednisolone equivalents. The primary outcome for incidence of SIHGLY was insignificant; post hoc analysis removing non-insulin-dependent diabetics narrowly missed significance between tertiles 1 and 3 (P = .056). CPH analysis found significant differences in SIHGLY between tertiles 1 and 2 (hazard ratio [HR], 1.68; 95% CI, 1.02-2.76) and tertile 1 and 3 (HR, 1.79; 95% CI, 1.13-2.84), further post hoc analysis resulted in a loss of significance for the CPH analysis. Of 21 non-insulin-dependent diabetics, 20 met event status. The Kaplan-Meier analysis results were insignificant.

Conclusions: Study results suggest that a link between larger corticosteroid doses and hyperglycemia incidence may exist, but it requires further study. RESULTS in non-insulin-dependent diabetics provide evidence for increased glucose monitoring upon initiation of corticosteroid therapy.

Citing Articles

Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

Golubic R, Mumbole H, Ismail M, Choo A, Baker O, Atha K Diabet Med. 2024; 42(3):e15475.

PMID: 39642210 PMC: 11823367. DOI: 10.1111/dme.15475.


Corticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease.

Johannesmeyer H, Moussavi K, Rambaran K, Kolyouthapong K Am J Med Open. 2024; 8:100027.

PMID: 39036518 PMC: 11256224. DOI: 10.1016/j.ajmo.2022.100027.


Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial.

Sivapalan P, Bikov A, Ulrik C, Lapperre T, Mathioudakis A, Hojberg Lassen M J Clin Med. 2021; 10(12).

PMID: 34205765 PMC: 8234000. DOI: 10.3390/jcm10122734.


Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease.

Sivapalan P, Bikov A, Jensen J Diagnostics (Basel). 2021; 11(2).

PMID: 33546498 PMC: 7913607. DOI: 10.3390/diagnostics11020236.


Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)? CON.

Marcos P, Lopez-Campos J Med Sci (Basel). 2018; 6(2).

PMID: 29890705 PMC: 6024798. DOI: 10.3390/medsci6020049.


References
1.
Goodman S, Berlin J . The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994; 121(3):200-6. DOI: 10.7326/0003-4819-121-3-199408010-00008. View

2.
Lipscombe L, Levesque L, Gruneir A, Fischer H, Juurlink D, Gill S . Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry. 2011; 19(12):1026-33. DOI: 10.1097/JGP.0b013e318209dd24. View

3.
Leuppi J, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T . Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309(21):2223-31. DOI: 10.1001/jama.2013.5023. View

4.
Walters J, Tan D, White C, Gibson P, Wood-Baker R, Walters E . Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; (9):CD001288. PMC: 11195634. DOI: 10.1002/14651858.CD001288.pub4. View

5.
Donihi A, Raval D, Saul M, Korytkowski M, DeVita M . Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006; 12(4):358-62. DOI: 10.4158/EP.12.4.358. View